GPX4 and myelodysplastic syndrome: To identify which kind of cell death was involved, MDS cells were treated with RSL3 alone or in combination with liproxstatin-1 (Lip-1; a ferroptosis inhibitor targeting GPX4), ferrostatin-1 (Fer-1; a ferroptosis inhibitor targeting SCL7A11), deferoxamine (DFO; a chelator), Z-VAD-FMK (an apoptosis inhibitor targeting caspase), chloroquine (CQ; an autophagy inhibitor), or necrostatin-1 (Nec-1; a necroptosis inhibitor) [29–31].